XML 22 R5.htm IDEA: XBRL DOCUMENT v3.25.3
Consolidated Statements of Operations and Comprehensive Loss - USD ($)
$ in Thousands
 12 Months Ended
Jul. 31, 2025
Jul. 31, 2024
REVENUE    
Total revenue $ 917 $ 637
COSTS AND EXPENSES    
General and administrative 13,781 8,854
Research and development 12,823 4,170
In-process research and development expense 89,861
Depreciation and amortization 288 225
Loss on impairment of goodwill 3,050
Loss from operations (29,159) (102,627)
Interest income 1,996 2,383
Loss on initial investment in Day Three upon acquisition (1,633)
Realized gain on available-for-sale securities 178 1,772
Realized loss on investment in equity securities (46)
Realized gain on investment - Cyclo 424
Unrealized (loss) gain on investment - Cyclo (5,144) 37
Unrealized (loss) gain on convertible notes receivable, due from Cyclo (719) 1,191
Unrealized gain on investment - Hedge Funds 63
Recovery of receivables from Cornerstone 31,305
Interest expense (658) (248)
Other income, net 310 118
Loss before income taxes (33,196) (67,261)
Benefit from income taxes 2,553 2,680
Equity in loss of Day Three (422)
Consolidated net loss (30,643) (65,003)
Net loss attributable to noncontrolling interests (123) (30,593)
Net loss attributable to Rafael Holdings, Inc. (30,520) (34,410)
OTHER COMPREHENSIVE LOSS    
Consolidated net loss (30,643) (65,003)
Unrealized gain on available-for-sale securities 247 464
Foreign currency translation adjustment 96 (53)
Comprehensive loss (30,300) (64,592)
Comprehensive loss attributable to noncontrolling interests (128) (30,595)
Comprehensive loss attributable to Rafael Holdings, Inc. $ (30,172) $ (33,997)
Loss per share attributable to common stockholders    
Basic (in Dollars per share) $ (1.04) $ (1.45)
Diluted (in Dollars per share) $ (1.04) $ (1.45)
Weighted average number of shares used in calculation of loss per share    
Basic (in Shares) 29,422,221 23,745,516
Diluted (in Shares) 29,422,221 23,745,516
Infusion Technology    
REVENUE    
Total revenue $ 93 $ 355
Rental – Third Party    
REVENUE    
Total revenue 197 174
Rental – Related Party    
REVENUE    
Total revenue 112 108
Product revenue    
REVENUE    
Total revenue 515
Infusion Technology revenue    
COSTS AND EXPENSES    
Cost of product revenue 106 154
Product revenue    
COSTS AND EXPENSES    
Cost of product revenue $ 28